Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials

Autor: Melvin J. Prince, Annette M. Chang, Yongming Qu, Shuyu Zhang, Julio Rosenstock, Edward J. Bastyr, Michel Marre
Jazyk: angličtina
Rok vydání: 2016
Předmět:
Blood Glucose
Male
endocrine system diseases
Endocrinology
Diabetes and Metabolism
Insulin Glargine
Type 2 diabetes
030204 cardiovascular system & hematology
Gastroenterology
law.invention
Polyethylene Glycols
0302 clinical medicine
Endocrinology
Randomized controlled trial
law
nocturnal hypoglycaemia
Insulin Lispro
Brief Report
Middle Aged
Themed Section‐bil
Circadian Rhythm
Nocturnal hypoglycaemia
Female
medicine.drug
Adult
medicine.medical_specialty
endocrine system
030209 endocrinology & metabolism
03 medical and health sciences
Double-Blind Method
Internal medicine
Internal Medicine
medicine
Humans
Dosing
Aged
Retrospective Studies
Glycated Hemoglobin
Type 1 diabetes
Insulin glargine
business.industry
Basal insulin
nutritional and metabolic diseases
basal insulin peglispro
medicine.disease
Hypoglycemia
Diabetes Mellitus
Type 1
Basal (medicine)
Diabetes Mellitus
Type 2
business
hypoglycaemia
Zdroj: Diabetes, Obesity & Metabolism
ISSN: 1463-1326
1462-8902
Popis: Basal insulin peglispro (BIL) is a novel basal insulin with hepato-preferential action, resulting from reduced peripheral effects. This report summarizes hypoglycaemia data from five BIL phase III studies with insulin glargine as the comparator, including three double-blind trials. Prespecified pooled analyses (n = 4927) included: patients with type 2 diabetes (T2D) receiving basal insulin only, those with T2D on basal-bolus therapy, and those with type 1 diabetes (T1D). BIL treatment resulted in a 36-45% lower nocturnal hypoglycaemia rate compared with glargine, despite greater reduction in glycated haemoglobin (HbA1c) and higher basal insulin dosing. The total hypoglycaemia rate was similar in patients with T2D on basal treatment only, trended towards being higher (10%) in patients with T2D on basal-bolus treatment (p = .053), and was 15% higher (p < .001) with BIL versus glargine in patients with T1D, with more daytime hypoglycaemia in the T1D and T2D groups who were receiving basal-bolus therapy. In T1D, during the maintenance treatment period (26-52 weeks), the total hypoglycaemia rate was not significantly different. There were no differences in severe hypoglycaemia in the T1D or T2D pooled analyses. BIL versus glargine treatment resulted in greater HbA1c reduction with less nocturnal hypoglycaemia in all patient populations, higher daytime hypoglycaemia with basal-bolus therapy in the T1D and T2D groups, and an associated increase in total hypoglycaemia in the patients with T1D.
Databáze: OpenAIRE
Externí odkaz: